Caliber Imaging & Diagnostics Names Robert T. Kelley to Vice President of U.S. Sales


BOSTON and ROCHESTER, N.Y., March 5, 2014 (GLOBE NEWSWIRE) -- Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., has named Robert T. Kelley to Vice President of U.S. Sales, effective immediately. Mr. Kelley had served as Caliber I.D.'s Director of Clinical Sales since joining the company in November 2011.

Mr. Kelley has nearly two decades of experience in medical sales, with expertise in capital medical equipment and a specialty in diagnostic imaging. Before arriving at Caliber I.D., Mr. Kelley, was Northeast Regional Territory Sales Manager at XHALE Corporation, where he oversaw sales of the HyGreen hand hygiene system and liaised with C-level healthcare personnel at a wide range of institutions. Previous to this he was Northeast Regional Territory Sales Manager at ONI Medical Systems (later acquired by GE Healthcare), where he oversaw sales of the Extremity 1.0T/1.5T MRI system to a range of healthcare facilities. Earlier, he served as Contrast Media and Delivery System Specialist for Covidien's Tyco Healthcare and Mallinckrodt divisions. Prior to this, he held sales and marketing positions at Radiology Corporation of America and Medical Resources. Mr. Kelley holds a BS degree in pre-medicine with an emphasis in medical therapeutic science and rehabilitation from Springfield College.

Mr. Kelley said, "In recent years, there have been tremendous advances made in medical technology, and in point-of-care diagnostic imaging in particular. Caliber's VivaScope® system is a prime example of this trend. Since arriving at the company in late 2011, I have enjoyed working with management to help convey the specific advantages of VivaScope to the medical community, and overseeing strategies that are designed to strengthen recognition and maximize sales of this game-changing technology. I believe consumer demand for VivaScope is growing at a significant rate, and as Vice President of U.S. Sales I intend to work to continue feeding that growth."

L. Michael Hone, Chief Executive Officer of Caliber I.D., said, "We are delighted to promote Bob to Vice President of Sales, just as we were truly fortunate when he agreed to join the company in 2011. As we continue to reach out to medical professionals to communicate the capabilities of our VivaScope system, we will continue to draw heavily on his experience and talent."

About Caliber Imaging & Diagnostics

Caliber Imaging & Diagnostics' proprietary, cutting-edge VivaScope(R) system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued or pending patents worldwide, VivaScope significantly improves outcomes and reduces costs, allowing physicians to quickly detect cancerous lesions that appear benign. VivaScope dramatically reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the cosmetics industry. For more information about Caliber I.D. and its products, please visit www.caliberid.com.

VivaScope(R) is a registered trademark of Caliber Imaging & Diagnostics.

Safe Harbor

This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.


            

Contact Data